Drug updated on 5/17/2024
Dosage Form | Tablet (oral; 75 mg, 100 mg) |
Drug Class | mu-opioid receptor agonist |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Eluxadoline (Viberzi) is used for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. It significantly improves IBS global symptoms and bowel movement frequency, showing better outcomes in improving these symptoms and abdominal pain compared to other drugs.
- The safety and effectiveness of Viberzi for treating IBS-D among adults were assessed in three systematic reviews/meta-analyses.
- Nocebo effects can significantly impact adverse event reporting in IBS trials, as indicated by high adverse events reported even within placebo groups, but this does not directly provide data on Viberzi's side effect profile.
- Compared to other opioid receptor modulators used for treating IBS-D, eluxadoline has a low rate of constipation development, which suggests it may have a preferable safety profile regarding this specific side effect.
- All reviewed drugs, including Viberzi, were found superior to placebo; however, alosetron ranked highest for efficacy, while rifaximin ranked highest for safety, indicating that eluxadoline might not be the safest or most effective option available.
- Detailed insights into population types and subgroup considerations beyond broad categorization into IBS-D are unavailable, hence no specific analyses comparing Viberzi's performance across different patient demographics or conditions could be made.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Viberzi (eluxadoline) Prescribing Information. | 2020 | Allergan USA, Inc., Madison, NJ |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. | 2022 | Gastroenterology |
Eluxadoline Versus Antispasmodics in the Treatment of Irritable Bowel Syndrome: An Adjusted Indirect Treatment Comparison Meta-analysis | 2022 | Frontiers in Pharmacology |
Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. | 2021 | Journal of Gastroenterology |
Canadian Association of Gastroenterology clinical practice guideline for the management of irritable bowel syndrome (IBS). | 2019 | Journal of the Canadian Association of Gastroenterology |